Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Cash & Equivalents (2016 - 2025)

Protalix BioTherapeutics (PLX) has 16 years of Cash & Equivalents data on record, last reported at $13.6 million in Q3 2025.

  • For Q3 2025, Cash & Equivalents fell 50.21% year-over-year to $13.6 million; the TTM value through Sep 2025 reached $13.6 million, down 50.21%, while the annual FY2024 figure was $19.8 million, 16.39% down from the prior year.
  • Cash & Equivalents reached $13.6 million in Q3 2025 per PLX's latest filing, down from $17.9 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $48.2 million in Q2 2023 and bottomed at $10.6 million in Q3 2021.
  • Average Cash & Equivalents over 5 years is $22.9 million, with a median of $19.8 million recorded in 2021.
  • Peak YoY movement for Cash & Equivalents: skyrocketed 8841.51% in 2021, then crashed 63.13% in 2022.
  • A 5-year view of Cash & Equivalents shows it stood at $39.0 million in 2021, then tumbled by 56.11% to $17.1 million in 2022, then skyrocketed by 38.12% to $23.6 million in 2023, then dropped by 16.39% to $19.8 million in 2024, then plummeted by 30.94% to $13.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $13.6 million in Q3 2025, $17.9 million in Q2 2025, and $19.5 million in Q1 2025.